in-PharmaTechnologist presents its latest round up movements in the pharma sector, including CytRx bolstering its manufacturing expertise and KV preparing its management as it strives to resume distribution.
CytRx has appointed Scott Geyer as its senior vice president (VP) of manufacturing. The appointment is intended to give CytRx the expertise needed to meet US Food and Drug administration (FDA) regulatory and manufacturing standards.
Geyer was most recently VP, technical operations at Cerimon Pharmaceuticals and has also held positions at TRF Pharma, Xencor, BioMarin Pharmaceuticals and Onyx Pharmaceuticals.
Thomas Silberg is to retire as president and CEO of APP Pharmaceuticals, with John Ducker being lined up as a replacement. Since 2006 Ducker has been a member of the management board of Fresenius Kabi, APP’s parent company, and is also responsible for its innovation centre.
KV Pharmaceutical has entered into agreement with David Van Vliet, its interim president and CEO, which will see him keep the position through to December 31 2011. He has served as interim president and CEO since December 2008.
The appointment is intended to provide continuity of leadership as KV seeks to resume the manufacture and distribution of products marketed by its subsidiaries, Ethex and Ther-Rx.
Laurence Skillern has left BioXell after the working relationship was terminated by mutual consent. Skillern joined BioXell as chief medical officer (CMO) on February 1 2009.
Nektar Therapeutics has promoted Lorianne Masuoka to the position of senior VP and CMO. Masuoka joined Nektar in August 2008 as VP of clinical development. She has 15 years experience in clinical R&D.